

February 3, 2020

The Manager – Listing  
**BSE Limited,**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Outcome of the Board Meeting held on Monday, February 3, 2020**

**Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN**

At the Board meeting of the Company held on Monday, February 3, 2020 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2019. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 3, 2020 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

  
**Pratap Rudra**  
Company Secretary & Legal Counsel

AstraZeneca Pharma India Limited  
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045  
Statement of unaudited financial results for the quarter and nine months ended 31 December 2019

Sl No.	Particulars	Rs in lakhs except for earnings per share data					
		3 months ended 31/12/2019	Previous 3 months ended 30/09/2019	Corresponding 3 months ended in the previous year 31/12/2018	9 months ended 31/12/2019	9 months ended 31/12/2018	Year ended 31/03/2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited
1	<b>Revenue</b>						
	a) Revenue from operations	22,386.28	20,848.31	21,519.40	63,690.72	53,799.16	72,829.43
	b) Other income	346.15	316.08	349.57	961.15	1,027.30	1,628.52
	<b>Total income</b>	<b>22,732.43</b>	<b>21,164.39</b>	<b>21,868.97</b>	<b>64,651.87</b>	<b>54,826.46</b>	<b>74,457.95</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	2,164.70	1,328.21	1,594.29	5,368.39	4,043.52	6,267.23
	(b) Purchase of stock-in-trade	7,675.58	6,358.21	4,156.63	18,701.43	8,892.33	16,983.88
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,708.52)	(270.94)	651.47	(1,518.64)	3,889.51	(137.78)
	(d) Employee benefits expense	5,255.49	5,216.35	5,108.91	15,545.25	13,698.84	19,739.86
	(e) Depreciation and amortisation expense	477.12	464.06	378.10	1,403.91	1,100.52	1,492.41
	(f) Selling, marketing and distribution expense	1,169.65	1,401.17	1,651.37	4,269.14	5,681.82	7,980.28
	(g) Other expenses	4,153.02	3,459.35	4,268.74	10,736.58	11,100.91	14,865.72
	(h) Finance cost (refer note 2)	27.13	28.36	-	85.03	-	-
	<b>Total expenses</b>	<b>19,214.17</b>	<b>17,984.77</b>	<b>17,809.51</b>	<b>54,591.09</b>	<b>48,407.45</b>	<b>67,191.60</b>
3	<b>Profit before exceptional and extraordinary items and tax (1-2)</b>	<b>3,518.26</b>	<b>3,179.62</b>	<b>4,059.46</b>	<b>10,060.78</b>	<b>6,419.01</b>	<b>7,266.35</b>
4	Exceptional items	-	-	-	-	-	-
5	<b>Profit before extraordinary items and tax (3+4)</b>	<b>3,518.26</b>	<b>3,179.62</b>	<b>4,059.46</b>	<b>10,060.78</b>	<b>6,419.01</b>	<b>7,266.35</b>
6	Extraordinary items	-	-	-	-	-	-
7	<b>Profit before tax (5+6)</b>	<b>3,518.26</b>	<b>3,179.62</b>	<b>4,059.46</b>	<b>10,060.78</b>	<b>6,419.01</b>	<b>7,266.35</b>
8	<b>Tax expense (refer note 3)</b>						
	- Current tax	881.34	514.68	1,114.91	2,665.55	1,816.26	1,667.83
	- Deferred tax	(33.25)	1,223.41	35.37	1,132.00	141.10	154.45
	<b>Total tax expense</b>	<b>848.09</b>	<b>1,738.09</b>	<b>1,150.28</b>	<b>3,797.55</b>	<b>1,957.36</b>	<b>1,822.28</b>
9	<b>Profit for the period (7-8)</b>	<b>2,670.17</b>	<b>1,441.53</b>	<b>2,909.18</b>	<b>6,263.23</b>	<b>4,461.65</b>	<b>5,444.07</b>
10	<b>Other comprehensive income</b>						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	107.26	(114.85)	(60.65)	(351.63)	139.01	(92.30)
	Income tax effect on above	(27.00)	(4.73)	21.19	88.50	(48.58)	32.25
	<b>Total other comprehensive income/ (loss), net of income tax</b>	<b>80.26</b>	<b>(119.58)</b>	<b>(39.46)</b>	<b>(263.13)</b>	<b>90.43</b>	<b>(60.05)</b>
	<b>Total comprehensive income for the period (9+10)</b>	<b>2,750.43</b>	<b>1,321.95</b>	<b>2,869.72</b>	<b>6,000.10</b>	<b>4,552.08</b>	<b>5,384.02</b>
11	<b>Paid-up equity share capital</b> (Face value of Rs 2/- per equity share)	<b>500.00</b>	<b>500.00</b>	<b>500.00</b>	<b>500.00</b>	<b>500.00</b>	<b>500.00</b>
12	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	-	-	29,580.50
13	<b>Earnings per equity share of Rs 2/- each (basic and diluted)</b>	<b>10.68</b>	<b>5.77</b>	<b>11.64</b>	<b>25.05</b>	<b>17.85</b>	<b>21.78</b>

*[Handwritten Signature]*



*[Handwritten Signature]*

AstraZeneca Pharma India Limited  
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045  
Statement of unaudited financial results for the quarter and nine months ended 31 December 2019

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 Effective 1 April 2019, the Company has adopted Ind AS 116, 'Leases'. Ind AS 116 introduces a single lessee accounting model and requires a lessee to recognise right-of-use assets and lease liabilities for all leases with a term of more than twelve months, unless the underlying asset is of a low value.  
  
The Company has used the 'modified retrospective approach' for transition from Ind AS 17, 'Leases', and consequently, comparatives for previous periods have not been adjusted. On transition, the Company has recorded lease liability at present value of future lease payments discounted using the incremental borrowing rate and has recognised the right-of-use asset at an amount equal to the lease liability and adjusted for prepaid lease payments.  
  
The adoption of Ind AS 116 has resulted in recognition of right-of-use assets of Rs.1,367.51 lakhs and lease liabilities of Rs.1,330.34 lakhs with a corresponding effect of Rs.12.98 lakhs on retained earnings on 1 April 2019. In the financial results for the quarter and nine months ended 31 December 2019, the nature of expense for leasing arrangements has changed from lease rent in previous periods to depreciation on the right-of-use assets and finance cost on the corresponding lease liabilities. The adoption of Ind AS 116 did not have a material impact on the results for the quarter ended 31 December 2019.
- 3 Pursuant to a notification of the Taxation Laws (Amendment) Ordinance 2019, the Company had opted to pay tax as per Section 115BAA at the income tax rate of 22% (plus applicable surcharge and cess). Consequently, during the quarter ended 30 September 2019, the Company has recognised the impact of remeasurement of the net deferred tax assets and the current tax charge.  
Accordingly, the excess current tax provision relating to quarter ended 30 June 2019 amounting to INR 353.62 lakhs was reversed in the Unaudited Statements of Financial Results in the quarter ended 30 September 2019. Similarly, the excess net deferred tax assets (including minimum alternate tax) of INR 1,246.56 lakhs was reversed in the Unaudited Statements of Financial Results in the quarter ended 30 September 2019.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 6 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 7 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 3 February 2020. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter and nine months ended 31 December 2019.

Place: Bengaluru  
Date: 03 February, 2020



By Order of the Board of Directors  
For AstraZeneca Pharma India Limited

  
Gagandeep Singh Bedi  
Managing Director





# Price Waterhouse & Co Chartered Accountants LLP

To  
The Board of Directors  
AstraZeneca Pharma India Limited  
Block N1, 12th Floor,  
Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road,  
Bengaluru – 560 045

## Independent Auditor's Report on the Statement of financial results

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended December 31, 2019 and the year to date results for the period April 1, 2019 to December 31, 2019, which are included in the accompanying 'Statement of unaudited financial results for the quarter and nine months ended December 31, 2019 (the "Statement")'. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP  
Firm Registration Number: 304026E/E-300009



Pradip Kanakia  
Partner  
Membership Number: 039985  
UDIN: 20039985AAAABM9181

Place: Bengaluru  
Date: February 03, 2020

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road  
Ulsoor, Bangalore-560 008  
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)